Published in AIDS Weekly, February 21st, 2000
"The push for an effective AIDS vaccine has been hampered, in part, by the inability to elicit a potent neutralizing antibody response against genetically diverse HIV-1 isolates," said K. Salzwedel and colleagues from the U.S. National Institutes of Health, Maryland. "Two human monoclonal antibodies (mAbs), 17b and 48d, have been described that bind a conserved region of gp120, overlapping the coreceptor-binding site, that becomes more exposed upon binding of Env to CD4. However, these mAbs neutralize virus only...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.